MedPath

Less Infections for the Diabetic Foot

Not Applicable
Completed
Conditions
Diabetic Foot
Interventions
Procedure: Surgical debridement (if needed)
Diagnostic Test: Microbiological sampling
Procedure: Revascularisation (if needed).
Device: Off-loading
Behavioral: Patient's education and instructions
Procedure: Wound debridement
Drug: Antibiotic duration
Registration Number
NCT03615807
Lead Sponsor
University Hospital, Geneva
Brief Summary

This is a randomized, unblinded, single-centre study. After eventual surgical debridement (not amputation), patients will be randomized to receive 1 of 2 targeted antibiotic regimens, in the ratio 1:1.

For diabetic toe osteomyelitis, the patients will be randomized between a 3 and a 6 week's arm, for soft tissue infections between 10 and 20 days. The final assessments used in the primary efficacy analysis will be obtained at the test-of-cure (TOC) visit approximately 60 days after treatment is stopped.

Detailed Description

Diabetic foot infections (DFI) are frequent and are associated with a high burden of morbidity, costs, recurrence risk or new episodes of infections. About two-third of recurrent DFI may reveal other microorganisms than in the previous period, suggesting new episodes of infection due to the underlying problem, and/or selection by prior antimicrobial therapy. Osteomyelitis in the diabetic toe is almost always established by contiguous spread of infection from a chronic ulcer. It occurs in up to 15% of patients with a diabetic foot ulcer and about 20% of all DFI (and over half of severe infections) involve bone at presentation. The severity of a diabetic foot infection is based on the local and systemic signs and symptoms of infection and has been categorically defined in the Infectious Disease Society of America guidelines for the "Diagnosis and Treatment of Diabetic Foot Infections" (IDSA guidelines).

Knowing the potential for poor outcomes, many clinicians have tended to treat DFIs with a long duration of antibiotic therapy, with many side effects, development and spreading of antibiotic resistance, and associated costs. Data from recent comparative trials has shown that 1-2 weeks is sufficient for most soft tissue infections, and 4 to 6 weeks appears adequate in those with (unresected) infected bone. Retrospective reviews over the past two decades have demonstrated that about two-thirds of selected patients with diabetic foot osteomyelitis can achieve remission with antibiotic therapy alone (i.e., without bone resection). One recent randomized trial found that treatment with only antibiotic therapy (given for 90 days) gave similar clinical outcomes to treatment with conservative surgery (removal only of the infected bone) along with just a short course of antibiotic therapy. Another randomized trial compared a 6-week against 12-week course of antibiotic therapy, without concomitant surgery, for diabetic foot osteomyelitis and also found similar outcomes.

Likewise, the optimal antibiotic duration for any skin and soft tissue infection is unknown. According to some databases of University of Geneva Hospitals, among 378 skin and soft tissue infections in 346, overall cure was achieved in 330 episodes (87%) after a median antibiotic administration of 15 days. In multivariate Cox regression analysis, duration of antibiotic therapy (HR 1.0, 95%CI 0.96-1.02) did not influence treatment failure among patients with positive MRSA carriage.

Our study intends to optimize the duration of antibiotic therapy in DFI; for skin and soft tissue infections as well as for diabetic toe osteomyelitis that is not amputated.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
182
Inclusion Criteria
  1. Age ≥ 18
  2. Diabetes mellitus
  3. Diabetic Foot Infections
  4. Surgical intervention to remove all necrotic tissue or tenotomy.
  5. Osteomyelitis limited to bone contact or cortical lesions in X-ray.
Exclusion Criteria
  1. Implanted device.
  2. More than 96 hours of systemic antibiotic therapy prior to inclusion
  3. Amputation
  4. Destructive osteomyelitis
  5. Concomitant infections requiring more than 14 days of antibiotic therapy.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Short antibiotic armAntibiotic duration10 days for soft tissue infections 3 weeks for osteomyelitis
Short antibiotic armRevascularisation (if needed).10 days for soft tissue infections 3 weeks for osteomyelitis
Short antibiotic armOff-loading10 days for soft tissue infections 3 weeks for osteomyelitis
Standard antibiotic armPatient's education and instructions20 days for soft tissue infections 6 weeks for osteomyelitis
Standard antibiotic armWound debridement20 days for soft tissue infections 6 weeks for osteomyelitis
Short antibiotic armSurgical debridement (if needed)10 days for soft tissue infections 3 weeks for osteomyelitis
Short antibiotic armWound debridement10 days for soft tissue infections 3 weeks for osteomyelitis
Standard antibiotic armAntibiotic duration20 days for soft tissue infections 6 weeks for osteomyelitis
Short antibiotic armMicrobiological sampling10 days for soft tissue infections 3 weeks for osteomyelitis
Short antibiotic armPatient's education and instructions10 days for soft tissue infections 3 weeks for osteomyelitis
Standard antibiotic armSurgical debridement (if needed)20 days for soft tissue infections 6 weeks for osteomyelitis
Standard antibiotic armMicrobiological sampling20 days for soft tissue infections 6 weeks for osteomyelitis
Standard antibiotic armRevascularisation (if needed).20 days for soft tissue infections 6 weeks for osteomyelitis
Standard antibiotic armOff-loading20 days for soft tissue infections 6 weeks for osteomyelitis
Primary Outcome Measures
NameTimeMethod
Number of Participants Experiencing Clinical Failure30-60 days

Visual and dichotomous evaluation regarding the numbers of clinical recurrence/failure

Secondary Outcome Measures
NameTimeMethod
Number of Participants Experiencing Adverse Events Related to the Antibiotic Therapy30-60 days

Adverse events related to the antibiotic therapy.

Trial Locations

Locations (1)

Geneva University Hospitals

🇨🇭

Geneva, Switzerland

© Copyright 2025. All Rights Reserved by MedPath